Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
Titel:
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
Auteur:
Piulats, J.M. Watkins, C. Costa-GarcĂa, M. del Carpio, L. Piperno-Neumann, S. Rutkowski, P. Hassel, J.C. Espinosa, E. de la Cruz-Merino, L. Ochsenreither, S. Shoushtari, A.N. Orloff, M. Salama, A.K.S. Goodall, H.M. Baurain, J.-F. Nathan, P.